Rheumatology
Cohort Study: Among patients with resolved Hepatitis B infections and concomitant autoimmune disease, exposure to prednisone doses greater than 20 mg/day were associated with a high risk for HBV reactivation or hepatitis flare.
21 Jan, 2022 | 09:39h | UTCAverage corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection – Annals of Rheumatic Disease (link to abstract – $ for full-text)
Commentary on Twitter
Patients with time-weighted average prednisone dose greater than 20 mg/day would be classified as the high risk for HBV reactivation or hepatitis flare. Prophylactic Anti-HBV therapy may be needed for these high-risk patientshttps://t.co/qLuirdyXDK pic.twitter.com/yDJ4c072qm
— ARD & RMD Open (@ARD_BMJ) December 23, 2021
Consensus statements for the assessment and management of non-radiographic axial spondyloarthritis.
21 Jan, 2022 | 09:26h | UTC
Systematic Review: Comparison of clinical manifestations in rheumatoid arthritis vs. spondyloarthritis.
21 Jan, 2022 | 09:24h | UTC
Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis.
20 Jan, 2022 | 08:52h | UTC
In a study with 1110 children with prolonged fever, MRP8/14 serum levels were validated as a diagnostic marker for systemic juvenile idiopathic arthritis.
14 Jan, 2022 | 08:07h | UTCMRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever – Rheumatology (link to abstract – $ for full-text)
Commentary: It is about time: the first validated biomarker for early diagnosis of sJIA – Rheumatology
Phase 2 RCT: In patients with generalized pustular psoriasis, Spesolimab improved lesions at one week but was associated with infections and systemic drug reactions.
14 Jan, 2022 | 08:01h | UTCTrial of Spesolimab for Generalized Pustular Psoriasis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Trial of Spesolimab for Generalized Pustular Psoriasis – Mount Sinai
RCT: In patients with immune-mediated inflammatory diseases (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn disease, or psoriasis) treated with Infliximab, a proactive therapeutic drug monitoring protocol was more likely to lead to sustained disease control.
14 Jan, 2022 | 07:57h | UTCEffect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Commentary on Twitter
Study found proactive therapeutic drug monitoring (TDM) compared with treatment without TDM during maintenance infliximab therapy was more likely to lead to sustained disease control over 52 weeks for patients with immune-mediated inflammatory diseases https://t.co/yfJjyADaOT pic.twitter.com/JtOfQxFFDS
— JAMA (@JAMA_current) December 21, 2021
Review: Large-vessel vasculitis.
8 Jan, 2022 | 22:50h | UTCLarge-vessel vasculitis – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Large-vessel vasculitis (if the link is paywalled, try this one)
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.
8 Jan, 2022 | 22:45h | UTCJanus kinase-targeting therapies in rheumatology: a mechanisms-based approach – Nature Reviews Rheumatology (if the link is paywalled, try this one)
Management of patellar tendinopathy: a systematic review and network meta-analysis of randomized studies.
16 Dec, 2021 | 08:35h | UTC
Pictorial Review: Spinal disorders mimicking infection.
5 Dec, 2021 | 23:10h | UTCSpinal disorders mimicking infection – Insights into Imaging
Retrospective Cohort Study: Except for Rituximab, most immunosuppressive medicines were not associated with increased risk of mechanical ventilation or death in patients hospitalized with Covid-19.
2 Dec, 2021 | 10:07h | UTCCommentaries:
What does endemic COVID-19 mean for the future of rituximab? – The Lancet Rheumatology
Study: Immune-suppressed not at higher risk of poor COVID outcomes – CIDRAP
Commentary on Twitter
NEW RESEARCH—Long-term use of immunosuppressive medicines and in-hospital #COVID19 outcomes: data from N3C shows no increased risk of mechanical ventilation or in-hospital death with the exception of #rituximab https://t.co/vEyTzfvK5q #LancetRheumatology
@JohnsHopkins pic.twitter.com/NqlttjGrpj— The Lancet Rheumatology (@TheLancetRheum) November 16, 2021
The musculoskeletal manifestations of Marfan Syndrome: diagnosis, impact, and management.
28 Nov, 2021 | 20:58h | UTC
2021 DORIS definition of remission in SLE: final recommendations from an international task force.
26 Nov, 2021 | 10:01h | UTC
Review: A Road Map of the Axial Spondyloarthritis Continuum.
24 Nov, 2021 | 08:27h | UTCA Road Map of the Axial Spondyloarthritis Continuum – Mayo Clinic Proceedings
RCT: Tofacitinib (oral drug) is an effective treatment in patients with polyarticular course juvenile idiopathic arthritis.
21 Nov, 2021 | 22:38h | UTCTofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
NEW in @TheLancet — Tofacitinib in juvenile idiopathic #arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial
Flare rate by week 44 was significantly lower with tofacitinib (29%) than with placebo (53%) https://t.co/28JRrbPf8e #JIA pic.twitter.com/JzxHLNmgym
— The Lancet Rheumatology (@TheLancetRheum) November 10, 2021
What Is the best maintenance therapy for ANCA vasculitis?
18 Nov, 2021 | 08:34h | UTC
Review: Antineutrophil cytoplasmic antibody-associated interstitial lung disease.
10 Nov, 2021 | 06:46h | UTC
CDC Guidance: Immunocompromised may need a fourth Covid-19 shot.
4 Nov, 2021 | 10:06h | UTCCommentaries:
Immunocompromised may need a fourth Covid-19 shot, CDC says – CNN
Some immunocompromised people can receive a 4th Covid shot, CDC says – NBC News
NICE Guideline | Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management.
31 Oct, 2021 | 20:03h | UTCCommentaries:
Chronic fatigue syndrome advice scraps exercise therapy – BBC
ME exercise therapy guidance scrapped by health watchdog Nice – The Guardian
RCT: Extended follow-up of local steroid injection for carpal tunnel syndrome.
28 Oct, 2021 | 09:46h | UTC
Commentary on Twitter
In carpal tunnel syndrome, this randomized trial of local steroid vs placebo injection shows similar symptom severity score improvement but a significant small reduction in rate of and longer time to surgery after steroid. @IsamAtroshi @jonasranstam https://t.co/s5LibRnFaV
— JAMA Network Open (@JAMANetworkOpen) October 22, 2021
Review: Thoracic involvement and imaging patterns in IgG4-related disease.
26 Oct, 2021 | 01:22h | UTCThoracic involvement and imaging patterns in IgG4-related disease – European Respiratory Review
Commentary on Twitter
Thoracic and lung involvement of IgG4-RD are heterogeneous and underevaluated. Peribronchovascular involvement and lymph node enlargement are most frequent patterns. Interstitial disease pattern seems to be associated with lower rate of treatment response. https://t.co/AMuLjPByut pic.twitter.com/ZmDrz6nK6g
— ERS publications (@ERSpublications) October 13, 2021
Cluster RCT: Increasing the dietary sources of calcium and protein (by providing additional milk, yogurt, and cheese) reduced hip fractures and falls in older adults in residential care.
22 Oct, 2021 | 10:21h | UTCNews release: Increasing dairy intake reduces falls and fractures among older care home residents – British Medical Journal
Commentary on Twitter
Increasing intake of foods rich in calcium and protein such as milk, yoghurt, and cheese, reduces falls and fractures in older adults living in residential care, finds a randomised controlled trial published @bmj_latest today https://t.co/QzozG4Odjb
— BMJ (@bmj_company) October 21, 2021
The Dutch Multidisciplinary Occupational Health Guideline to Enhance Work Participation Among Low Back Pain and Lumbosacral Radicular Syndrome Patients.
7 Oct, 2021 | 10:18h | UTC
Evidence and consensus-based recommendations for non-pharmacological treatment of fatigue, hand function loss, Raynaud’s phenomenon, and digital ulcers in patients with systemic sclerosis.
7 Oct, 2021 | 10:19h | UTC